@article {Tandone381作者={卡曼经脉和大卫Tirschwell地下水面Longstreth, Jr史密斯和布莱恩和Nazem Akoum}, title ={栓塞中风待定的来源与房颤心房纤维化没有},体积={93}={4},页面= {e381——e387} = {2019}, doi = {10.1212 / WNL。出版商0000000000007827}= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={客观检查假设心房纤维化和相关心房心脏病可能在cardioembolic中风的因首页果路径独立于心房纤颤(房颤)通过比较心房纤维化负担栓塞中风患者之间不确定的来源(、因),房颤患者和健康对照组。方法我们使用late-gadolinium-enhancement MRI比较心房纤维化在10对患者、因控制(没有中风,没有房颤)和10房颤患者。纤维化组之间比较,控制中风的危险因素。结果平均年龄是51 {\ textpm} 15年,43 \ %的参与者是女性。比控制、因有更多患者心房纤维化(16.8 {\ textpm} \ % 5.7 vs 10.6 {\ textpm} \ % 5.7, p = 0.019)和类似的纤维化相比,房颤患者(17.8 {\ textpm} \ % 4.8, p = 0.65)。每四分位数、因纤维化的优势比分别为3.22(95 \ %可信区间(CI) 1.11 {\ textendash} 9.32, p = 0.031,未调整)和3.17 (95 \ % CI 1.05 {\ textendash} 9.52, p = 0.041, CHA2DVASc分数调整)。\ > 12 \ %纤维化患者有较高的比例、因(77.8 vs 27.3 \ \ % %, p = 0.02),和\ > 20 \ %纤维化患者的比例最高、因(4,5).Conclusions相比表现出类似的心房纤维化患者、因房颤患者比健康对照组和纤维化。在控制了纤维化与、因中风危险因素,支持假设纤维化的因果路径独立于AF cardioembolic中风。需要前瞻性研究来评估抗凝的作用在初级和二级预防中风患者心房纤维化。房颤=心房纤维性颤动;阿提克斯= Apixaban栓塞性中风的治疗不确定的来源;CRYSTAL-AF =连续心脏监测评估研究不明原因引起的中风后心房颤动;不确定的来源、因=栓塞性中风;LA =左心房; LGE=late gadolinium enhancement; NAVIGATE-ESUS=Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS); NT-proBNP=N-terminal pro-B-type natriuretic peptide; PFO=patent foramen ovale; RE-SPECT ESUS=Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source; WARSS=Warfarin-Aspirin Recurrent Stroke Study}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/93/4/e381}, eprint = {//www.ez-admanager.com/content/93/4/e381.full.pdf}, journal = {Neurology} }